Smoking is a major risk factor for many health conditions, including lung cancer and cardiovascular disease (CVD). Although nicotine replacement therapy (NRT) and behavioral encouragement are the most effective ways to quit smoking, the high relapse rate indicates the need to reconsider smoking cessation strategies.
For example, 27% of smokers interested in quitting use electronic cigarette products, while 18% use NRT. However, evidence regarding the impact of electronic cigarettes on cardiovascular health is limited. Therefore, this randomized controlled trial aims to compare the CVD outcomes of smokers randomly assigned to receive nicotine-containing electronic cigarettes, nicotine-free electronic cigarettes, or NRT treatment at 3 and 6 month follow-ups.
A study conducted on a group of 248 individuals who smoked at least 10 cigarettes a day and aimed to quit smoking measured cardiovascular disease (CVD) outcomes such as flow-mediated dilation (FMD), mean arterial pressure (MAP), and skin microvascular responses to acetylcholine (ACh) and nitroprusside (SNP). The study found that all three groups demonstrated improvement in FMD at 3 months (β=3.33, 95%CI 2.61-4.05, p = 0.0001) and 6 months (β=2.69, 95%CI 2.02-3.35, p < 0.0001). However, there were no significant differences in other CVD outcomes such as skin microvascular responses to ACh and SNP, and MAP between the three treatment groups. Overall, the study concludes that quitting smoking leads to improved CVD outcomes at 3 and 6 months, but there is no significant difference in improvement between the treatment groups.
Statement
This article is compiled from third-party information and is intended for industry exchange and learning purposes only.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article's content. The translation of this article is only intended for industry communication and research purposes.
Due to limitations in our proficiency in translation, our translated article may not fully capture the intended meaning of the original text. We advise readers to refer to the original article for accuracy.
2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or international issues and positions.
Compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
